ARCHIVES

Cancer research poised for a “platinum age” as a “golden age” ends, NCI director tells AACR annual meeting.

This article is from The Cancer Letter archive.

Vol. 31 No. 17 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

AACR settles dispute with Toronto Convention Center and hotels over cancellation of 2003 annual meeting. Travelers Insurance covered AACR’s claim.

April 15, 2005

Dispute At City of Hope Pits Center Against For-Profit Physician Group.

May 28, 2010

NCI’s Professional Judgment Budget Outlines Spending of $7.2 Billion

February 13, 2009

Troubled Allegheny Cuts Cancer Programs; Institution Holds Grants for NSABP, ECOG

July 10, 1998

Are Cancer Drugs Getting Better? FDA’s Richard Pazdur Says “Yes”

February 14, 2014